ATE247481T1 - Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren - Google Patents

Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren

Info

Publication number
ATE247481T1
ATE247481T1 AT94916460T AT94916460T ATE247481T1 AT E247481 T1 ATE247481 T1 AT E247481T1 AT 94916460 T AT94916460 T AT 94916460T AT 94916460 T AT94916460 T AT 94916460T AT E247481 T1 ATE247481 T1 AT E247481T1
Authority
AT
Austria
Prior art keywords
peptide antagonists
glutamic acid
nmda receptors
novel peptide
nmda
Prior art date
Application number
AT94916460T
Other languages
English (en)
Inventor
J P Bourguignon
Original Assignee
Neuronz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuronz Ltd filed Critical Neuronz Ltd
Application granted granted Critical
Publication of ATE247481T1 publication Critical patent/ATE247481T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT94916460T 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren ATE247481T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19939301667A SE9301667D0 (sv) 1993-05-14 1993-05-14 New use
PCT/SE1994/000454 WO1994026301A1 (en) 1993-05-14 1994-05-16 New peptide antagonists at glutamate and nmda receptors

Publications (1)

Publication Number Publication Date
ATE247481T1 true ATE247481T1 (de) 2003-09-15

Family

ID=20389945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916460T ATE247481T1 (de) 1993-05-14 1994-05-16 Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren

Country Status (12)

Country Link
US (2) US5804550A (de)
EP (1) EP0697886B1 (de)
JP (1) JP3819932B2 (de)
AT (1) ATE247481T1 (de)
AU (1) AU685123B2 (de)
CA (1) CA2162924C (de)
DE (1) DE69433058T2 (de)
DK (1) DK0697886T3 (de)
ES (1) ES2204916T3 (de)
NZ (1) NZ266559A (de)
SE (1) SE9301667D0 (de)
WO (1) WO1994026301A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017204A1 (en) * 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
GB9611584D0 (en) * 1996-06-04 1996-08-07 Univ Edinburgh Neurotransmitters
DE60232880D1 (de) 2001-05-24 2009-08-20 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
WO2003086323A2 (en) * 2002-04-05 2003-10-23 Neuronz Limited Compositions and methods for immunomodulation
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
EP1529533A1 (de) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Behandlung von ischämischen Gehirnschäden mit Wachstumshormon-Sekretionsförderern
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596B1 (en) 2013-01-29 2023-12-06 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EA201892657A1 (ru) 2016-05-19 2019-05-31 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
WO2018026792A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
US10961189B2 (en) 2016-08-01 2021-03-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017557A (en) * 1987-07-24 1991-05-21 Industria Farmaceutica Serono S.P.A. Treatment of infertility with somatotrophin releasing factor
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
CA2114251C (en) * 1991-08-01 2007-11-06 Peter Gluckman Igf-1 to improve the neural condition

Also Published As

Publication number Publication date
JPH08510214A (ja) 1996-10-29
EP0697886A1 (de) 1996-02-28
EP0697886B1 (de) 2003-08-20
AU685123B2 (en) 1998-01-15
WO1994026301A1 (en) 1994-11-24
US5804550A (en) 1998-09-08
DE69433058T2 (de) 2004-06-03
CA2162924C (en) 2008-12-30
CA2162924A1 (en) 1994-11-24
DK0697886T3 (da) 2003-10-20
DE69433058D1 (de) 2003-09-25
JP3819932B2 (ja) 2006-09-13
US20020115594A1 (en) 2002-08-22
AU6810894A (en) 1994-12-12
SE9301667D0 (sv) 1993-05-14
NZ266559A (en) 2000-12-22
ES2204916T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
ATE247481T1 (de) Neuartige peptidantagonisten der glutaminsäure- und nmda-rezeptoren
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
NO951613L (no) Ikke-peptidyl tachykinin reseptorantagonister
ES2135414T3 (es) Antagonistas del receptor 5-ht4.
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
UA27741C2 (uk) Похідні [2-(аміно-3,4-діоксо-1-циклобутен-1-іл)-аміно]-алкілових кислот для запобігання конвульсій і нейродегенеративних розладів та спосіб запобігання конвульсій та нейродегенеративних розладів
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
ATE86247T1 (de) 3-indolpyruvsaeure-derivate und deren verwendung als arznemittel.
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
DK0869808T3 (da) Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
ATE223712T1 (de) Pharmazeutische zusammensetzung von l-dopa ethyl ester
MXPA02001340A (es) Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
TR199700653A2 (xx) N-(4-aril-tiazol-2-il)-sulfonamid t�revleri ve onlar�n kullan�m�.
EA199800376A1 (ru) Антагонисты рецепторов возбудительной аминокислоты
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
DE68905845D1 (de) Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
DE69621799D1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
HUT67237A (en) Excitatory amino acid antagonists indole derivatives, their preparation and pharmaceutical compositions comprising them
ATE148989T1 (de) Partielle agonisten der strychnin unempfindlichen glycinmodulierenden stelle des n-methyl-d- aspartat-rezeptor-komplexes als neuropsycho- pharmakologische wirkstoffe
DE69510545D1 (de) Cck oder gastrin modulierende 5-heterocyclicyl-1,5-benzodiazepine
ES2135412T3 (es) Uso de antagonistas o agonistas parciales del receptor 5-ht 1a para el tratamiento y la prevencion de trastornos cognitivos.
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties